LDS/Medical Tests/Duchenne/Becker Muscular Dystrophy (DMD) Gene Mutation Analysis

Duchenne/Becker Muscular Dystrophy (DMD) Gene Mutation Analysis

Duchenne muscular dystrophy (DMD) is an x-linked genetic disorder characterized by progressive muscle atrophy beginning before age 5. It affects skeletal muscle, the smooth muscle of the gastrointestinal tract, bladder and cardiac muscles. Affected individuals may have skeletal muscle weakness making them wheelchair dependent by age 11 or 12. Death may occur due to cardiomyopathy or respiratory failure as patients approach adulthood. Becker muscular dystrophy (BMD) is a similar but typically milder form of muscular dystrophy with more varied symptoms in comparison to DMD. Individuals with BMD are often ambulatory into their thirties although they may suffer from cardiomyopathy. DMD and BMD are caused by mutations in the dystrophin (DMD) gene, which is located on the X chromosome at band p21. Since DMD and BMD are inherited in an X-linked manner, the conditions primarily affect males. Women carrying a mutation in DMD are asymptomatic; however, they do have an increased risk for cardiomyopathy. The incidence of DMD and BMD in boys is approximately 1 in 3500 and 1 in 18,500, respectively. Molecular genetic testing is important in establishing the nature of the mutation and provides important prognostic information. However, because of the large size of the DMD gene and the complex nature of the mutations, molecular testing may require the use of multiple techniques. About 70% of DMD/BMD patients are diagnosed based of deletions/duplication analysis and remaining 30% of patients with small mutations requires sequence analysis. Further analysis of dystrophin by Western Blot is used to further differentiate DMD from BMD. In DMD dystrophin is < 5% of normal, BMD is > 20% of normal and ‘intermediate’ cases have levels 5-20% of normal and intermediate clinical features.
  • Confirm clinical diagnosis of Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD)
  • Differential diagnosis BMD from DMD for prognostic advantages
  • Determination of carrier status in family member at risk for DMD or BMD
  • Prenatal diagnosis of DMD or BMD in at-risk pregnancies

Normal:

  • No mutation in DMD gene (molecular confirmation after deletion/duplication analysis and sequence analysis)

Abnormal:

  • If a mutation is detected in women it indicates she is a carrier.
  • If a mutation is detected in a man, it confirms DMD/BMD
  • In addition, studies suggest when large duplications are detected in female carriers of DMD, it may increase their risk in developing symptoms related to the disease

Negative for mutations analyzed (No deletions or duplications were identified)

Multiplex Ligation-Dependent Probe Amplification (MLPA), array comparative genomic hybridization (aCGH), Massively Parallel Sequencing, direct sequence analysis and/or next-generation sequencing (NGS).

Whole blood, Amniotic fluid, Chorionic villi, Confluent cultured cells.

Stability

Whole blood

  • Ambient (72 hours)
  • Refrigerated: 7 days

Confluent cultured cells and Amniotic fluid, Chorionic villi

  • Refrigerated: 5-7 days
  • Frozen: Unacceptable
Serum creatine kinase (CK) concentration blood enzyme test, muscle biopsy. Dystrophin analysis by Western Blot.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login